Maverix Medical, a Menlo Park, CA-based dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., acquired Cirrus Bio, a Phoeniz, AZ-based provider of multiomic solutions for the diagnosis and management of diseases.
The amount of the deal was not disclosed.
Led by David Mallery (CEO) and Scott Morris(CSO), Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role in clinical outcomes.
With the support of its financial sponsors and advisors, KKR and Hologic, Maverix Medical continues to invest in both development- and commercial-stage lung cancer companies and add opportunities to collaborate with innovators, entrepreneurs, clinicians, and industry leaders.
As part of the acquisition, Maverix also announced the formation of a dedicated diagnostic division called Maverix Dx that will develop, invest in, acquire, and bring to market a suite of diagnostic tools for lung cancer. David Mallery will serve as the Chief Executive Officer of Maverix Dx and Scott Morris as the Chief Scientific Officer. In these roles, they will continue to develop new diagnostic technologies, while also driving platform M&A and strategic investments.
